MA35124B1 - Pyrazolo[4,3-d] - Google Patents
Pyrazolo[4,3-d]Info
- Publication number
- MA35124B1 MA35124B1 MA36430A MA36430A MA35124B1 MA 35124 B1 MA35124 B1 MA 35124B1 MA 36430 A MA36430 A MA 36430A MA 36430 A MA36430 A MA 36430A MA 35124 B1 MA35124 B1 MA 35124B1
- Authority
- MA
- Morocco
- Prior art keywords
- diseases
- kinase
- compounds
- mylk
- lrrk2
- Prior art date
Links
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 101000941879 Homo sapiens Leucine-rich repeat serine/threonine-protein kinase 2 Proteins 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 abstract 1
- 101150040007 MYLK gene Proteins 0.000 abstract 1
- 102000003505 Myosin Human genes 0.000 abstract 1
- 108060008487 Myosin Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 229940088597 hormone Drugs 0.000 abstract 1
- 239000005556 hormone Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 210000000952 spleen Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161517582P | 2011-04-21 | 2011-04-21 | |
| PCT/EP2012/001737 WO2012143144A1 (en) | 2011-04-21 | 2012-04-23 | Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35124B1 true MA35124B1 (fr) | 2014-05-02 |
Family
ID=46017783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA36430A MA35124B1 (fr) | 2011-04-21 | 2013-11-14 | Pyrazolo[4,3-d] |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9802937B2 (enExample) |
| EP (1) | EP2699579B1 (enExample) |
| JP (1) | JP6222776B2 (enExample) |
| KR (1) | KR101649611B1 (enExample) |
| CN (1) | CN103492389B (enExample) |
| AP (1) | AP2013007253A0 (enExample) |
| AU (1) | AU2012244550C1 (enExample) |
| BR (1) | BR112013026521A2 (enExample) |
| CA (1) | CA2831634C (enExample) |
| CL (1) | CL2013003051A1 (enExample) |
| CO (1) | CO6831982A2 (enExample) |
| CR (1) | CR20130536A (enExample) |
| CU (1) | CU20130143A7 (enExample) |
| EA (1) | EA029040B1 (enExample) |
| EC (1) | ECSP13012982A (enExample) |
| GT (1) | GT201300255A (enExample) |
| IL (1) | IL228968A (enExample) |
| MA (1) | MA35124B1 (enExample) |
| MX (1) | MX363696B (enExample) |
| PE (1) | PE20140928A1 (enExample) |
| PH (1) | PH12013502185A1 (enExample) |
| SG (1) | SG194549A1 (enExample) |
| TN (1) | TN2013000419A1 (enExample) |
| TW (1) | TWI606049B (enExample) |
| WO (1) | WO2012143144A1 (enExample) |
| ZA (1) | ZA201307839B (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2828824A1 (en) * | 2011-03-28 | 2012-10-04 | F. Hoffmann-La Roche Ag | Thiazolopyrimidine compounds |
| JP5918848B2 (ja) | 2011-04-21 | 2016-05-18 | ギリアード サイエンシーズ， インコーポレイテッド | ベンゾチアゾール化合物およびその薬学的使用 |
| AU2012244550C1 (en) | 2011-04-21 | 2017-06-22 | Origenis Gmbh | Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors |
| US9376392B2 (en) | 2012-01-04 | 2016-06-28 | Gilead Sciences, Inc. | 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS |
| US9284323B2 (en) | 2012-01-04 | 2016-03-15 | Gilead Sciences, Inc. | Naphthalene acetic acid derivatives against HIV infection |
| AR090650A1 (es) | 2012-04-12 | 2014-11-26 | Alcon Res Ltd | Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo |
| US20120323214A1 (en) * | 2012-05-16 | 2012-12-20 | Totada R Shantha | Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis |
| CA2878054C (en) | 2012-06-29 | 2018-09-11 | Pfizer Inc. | Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors |
| US9637491B2 (en) * | 2012-10-19 | 2017-05-02 | Origenis Gmbh | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors |
| EP2964221B1 (en) | 2013-03-04 | 2017-12-06 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| WO2014134776A1 (en) | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| WO2014134772A1 (en) | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| WO2014134774A1 (en) | 2013-03-04 | 2014-09-12 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| TW201534597A (zh) | 2013-06-20 | 2015-09-16 | Ab Science | 作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物 |
| WO2015026683A1 (en) * | 2013-08-22 | 2015-02-26 | Merck Sharp & Dohme Corp. | Compounds inhibiting leucine-rich repeat kinase enzyme activity |
| CN105828823B (zh) | 2013-10-18 | 2019-06-14 | 美国印第安纳大学研究和技术公司 | 乙型肝炎病毒组装效应物 |
| JP6487921B2 (ja) | 2013-12-17 | 2019-03-20 | ファイザー・インク | ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン |
| RU2016134751A (ru) * | 2014-01-29 | 2018-03-02 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Соединения |
| UA118369C2 (uk) | 2014-01-29 | 2019-01-10 | Глаксосмітклайн Інтеллектьюел Проперті Девелопмент Лімітед | Сполуки, що інгібують активність lrrk2 кінази |
| CN106232118A (zh) | 2014-04-25 | 2016-12-14 | 辉瑞大药厂 | 杂芳族化合物及其作为多巴胺d1配体的用途 |
| WO2016007540A2 (en) | 2014-07-10 | 2016-01-14 | The J. David Gladstone Institutes | Compositions and methods for treating dengue virus infection |
| EP3256475A4 (en) * | 2015-02-13 | 2019-02-13 | Dana-Farber Cancer Institute, Inc. | LRRK2 INHIBITORS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
| EP3283472B1 (en) | 2015-04-17 | 2021-04-14 | Indiana University Research & Technology Corporation | Hepatitis b viral assembly effectors |
| CN108349910A (zh) * | 2015-06-26 | 2018-07-31 | 卡德门企业有限公司 | 葡萄糖摄取抑制剂 |
| US10729691B2 (en) | 2015-06-26 | 2020-08-04 | Kadmon Corporation, Llc | Treatment of infectious diseases with glucose uptake inhibitors |
| WO2017046675A1 (en) | 2015-09-14 | 2017-03-23 | Pfizer Inc. | Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors |
| US9762007B2 (en) | 2016-02-10 | 2017-09-12 | Dish Network L.L.C. | Push on connector |
| US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
| CN109923114B (zh) | 2016-09-09 | 2022-11-01 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物和其用于治疗癌症的用途 |
| WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| US10280164B2 (en) | 2016-09-09 | 2019-05-07 | Incyte Corporation | Pyrazolopyridone compounds and uses thereof |
| EP3528813B1 (en) | 2016-09-30 | 2025-04-16 | ABS Development 1, Inc. | P2x3 and/or p2x2/3 compounds and methods |
| CN106667990A (zh) * | 2016-11-17 | 2017-05-17 | 郑州郑先医药科技有限公司 | 一种治疗风湿病的药物 |
| CN106620315A (zh) * | 2016-11-17 | 2017-05-10 | 郑州郑先医药科技有限公司 | 一种用于治疗风湿病的药物组合物 |
| US20180153922A1 (en) | 2016-12-06 | 2018-06-07 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Inhibition of expansion and function of pathogenic age-associated b cells and use for the prevention and treatment of autoimmune disease |
| CN106580974A (zh) * | 2016-12-06 | 2017-04-26 | 郑州郑先医药科技有限公司 | 一种治疗脊髓损伤的西药组合物及其应用 |
| US11364237B2 (en) | 2017-02-07 | 2022-06-21 | Oncocross Co., Ltd. | Composition for inhibiting cancer metastasis and treating cancer |
| WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| AU2018256459B2 (en) * | 2017-04-21 | 2023-12-07 | Ikena Oncology, Inc. | Indole AHR inhibitors and uses thereof |
| US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
| CN108178760B (zh) * | 2017-12-27 | 2020-02-18 | 安徽医科大学 | 一种嘧啶并吡唑杂环化合物、制备方法、用途 |
| US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| AU2019223955B2 (en) | 2018-02-20 | 2024-06-13 | Incyte Corporation | N-(phenyl)-2-(phenyl)pyrimidine-4-carboxamide derivatives and related compounds as HPK1 inhibitors for treating cancer |
| WO2019162964A1 (en) * | 2018-02-23 | 2019-08-29 | Indian Institute Of Science | Anti-tubercular composition, and combinatorial implementations thereof |
| US10689386B2 (en) | 2018-03-07 | 2020-06-23 | Duquesne University Of The Holy Spirit | Pyrazolo[4,3-d]pyrimidines as antitumor agents |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| US11111247B2 (en) | 2018-09-25 | 2021-09-07 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
| CN109867800B (zh) * | 2019-04-01 | 2021-04-09 | 江西理工大学 | 一种镉基金属-有机框架及其制备方法 |
| AU2020279686B2 (en) * | 2019-05-21 | 2025-08-28 | Voronoi Inc. | N-containing heteroaryl derivative and pharmaceutical composition comprising same as active ingredient for prevention or treatment of cancer |
| WO2020247756A1 (en) * | 2019-06-05 | 2020-12-10 | Forcyte Biotechnologies, Inc. | Small molecules to relax uterine smooth muscle contractions |
| US20220249509A1 (en) * | 2019-07-05 | 2022-08-11 | Icahn School Of Medicine At Mount Sinai | Method for preventing hair loss |
| WO2021026180A1 (en) | 2019-08-06 | 2021-02-11 | Incyte Corporation | Solid forms of an hpk1 inhibitor |
| CN110876752B (zh) * | 2019-11-18 | 2021-04-30 | 暨南大学 | 长链非编码rna nron功能基序在制备抑制骨吸收及防治骨质疏松药物中的应用 |
| US11591339B2 (en) | 2019-11-26 | 2023-02-28 | Ikena Oncology, Inc. | Solid forms of (R)-N-(2-(5-fluoropyridin-3-yl)-8-isopropylpyrazolo[ 1,5-a][1,3,5]triazin-4-yl)-2,3,4,9-tetrahydro-1H-carbazol-3-amine maleate as aryl hydrocarbon receptor (AHR) inhibitors |
| WO2022093685A1 (en) * | 2020-10-26 | 2022-05-05 | Neuron23, Inc. | Methods of treatment and diagnosis of parkinson's disease associated with wild-type lrrk2 |
| US20240287079A1 (en) * | 2021-08-31 | 2024-08-29 | Japan Tobacco Inc. | 6-aminopyrazolopyrimidine compound and pharmaceutical use thereof |
| WO2023076404A1 (en) | 2021-10-27 | 2023-05-04 | Aria Pharmaceuticals, Inc. | Methods for treating systemic lupus erythematosus |
| EP4618975A2 (en) * | 2022-11-16 | 2025-09-24 | Vyrnwy Therapeutics, Inc. | Inhibitors of tyk2 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4469868A (en) * | 1982-05-24 | 1984-09-04 | Warner-Lambert Company | Alkylimidazo[1,2-c]pyrazolo[3,4-e]pyrimidines |
| GB8306481D0 (en) * | 1983-03-09 | 1983-04-13 | Beecham Group Plc | Compounds |
| US5360720A (en) | 1993-10-08 | 1994-11-01 | Alcon Laboratories, Inc. | Method of preparing human conjunctival mast cells for mast cell stabilization assays |
| US5723608A (en) * | 1996-12-31 | 1998-03-03 | Neurogen Corporation | 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands |
| US6531475B1 (en) * | 1998-11-12 | 2003-03-11 | Neurocrine Biosciences, Inc. | CRF receptor antagonists and methods relating thereto |
| DE19942474A1 (de) * | 1999-09-06 | 2001-03-15 | Merck Patent Gmbh | Pyrazolo[4,3-d]pyrimidine |
| DE10113710A1 (de) | 2001-03-16 | 2002-09-26 | Joerg Rademann | Oxoammoniumsalze sowie deren Verwendung |
| GB0106661D0 (en) * | 2001-03-16 | 2001-05-09 | Pfizer Ltd | Pharmaceutically active compounds |
| EP1348707B1 (en) * | 2002-03-28 | 2010-08-25 | Ustav Experimentalni Botaniky AV CR, v.v.i. (Institute of Experimental Botany Academy of Sciences of the Czech Republic, PRO) | Pyrazolo[4,3-d]pyrimidines, processes for their preparation and methods for therapy |
| US20030139427A1 (en) * | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
| DE60326646D1 (de) | 2002-12-18 | 2009-04-23 | Vertex Pharma | Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen |
| EP1752457B1 (en) * | 2004-06-02 | 2014-03-19 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compound |
| US8227475B2 (en) | 2005-05-12 | 2012-07-24 | Pfizer Inc. | Anhydrous crystalline forms of N-[1-(2-ethoxyethyl)-5-(N-ethyl-N-methylamino)-7-(4-methylpyridin-2-yl-amino)-1H-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide |
| US20090234117A1 (en) | 2005-05-27 | 2009-09-17 | Toshihiko Kashiwagi | Pyrazolopyrimidine Derivative |
| JP2007055940A (ja) | 2005-08-24 | 2007-03-08 | Astellas Pharma Inc | ピラゾロピリミジン誘導体 |
| NL2000291C2 (nl) | 2005-11-10 | 2009-02-17 | Pfizer Prod Inc | 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan. |
| KR20090103897A (ko) * | 2006-12-28 | 2009-10-01 | 다이쇼 세이야꾸 가부시끼가이샤 | 피라졸로피리미딘 화합물 |
| NZ587039A (en) | 2008-02-13 | 2013-01-25 | Gilead Connecticut Inc | 6-aryl-imidazo[1, 2-a]pyrazine derivatives, method of making, and method of use thereof |
| SG171993A1 (en) | 2008-12-08 | 2011-07-28 | Gilead Connecticut Inc | Imidazopyrazine syk inhibitors |
| WO2010118367A2 (en) | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Antiviral pyrimidines |
| JP5918693B2 (ja) | 2009-05-05 | 2016-05-18 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | Ｅｇｆｒ阻害剤及び疾患の治療方法 |
| AU2012244550C1 (en) | 2011-04-21 | 2017-06-22 | Origenis Gmbh | Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors |
| AR090650A1 (es) | 2012-04-12 | 2014-11-26 | Alcon Res Ltd | Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo |
-
2012
- 2012-04-23 AU AU2012244550A patent/AU2012244550C1/en active Active
- 2012-04-23 TW TW101114348A patent/TWI606049B/zh active
- 2012-04-23 SG SG2013077920A patent/SG194549A1/en unknown
- 2012-04-23 JP JP2014505544A patent/JP6222776B2/ja active Active
- 2012-04-23 PH PH1/2013/502185A patent/PH12013502185A1/en unknown
- 2012-04-23 CA CA2831634A patent/CA2831634C/en active Active
- 2012-04-23 EA EA201301184A patent/EA029040B1/ru unknown
- 2012-04-23 WO PCT/EP2012/001737 patent/WO2012143144A1/en not_active Ceased
- 2012-04-23 MX MX2013012294A patent/MX363696B/es unknown
- 2012-04-23 CN CN201280019429.4A patent/CN103492389B/zh active Active
- 2012-04-23 BR BR112013026521A patent/BR112013026521A2/pt not_active Application Discontinuation
- 2012-04-23 EP EP12717198.1A patent/EP2699579B1/en active Active
- 2012-04-23 AP AP2013007253A patent/AP2013007253A0/xx unknown
- 2012-04-23 US US13/506,510 patent/US9802937B2/en active Active
- 2012-04-23 KR KR1020137030320A patent/KR101649611B1/ko active Active
- 2012-04-23 PE PE2013002376A patent/PE20140928A1/es active IP Right Grant
-
2013
- 2013-10-14 TN TNP2013000419A patent/TN2013000419A1/fr unknown
- 2013-10-18 GT GT201300255A patent/GT201300255A/es unknown
- 2013-10-20 IL IL228968A patent/IL228968A/en active IP Right Grant
- 2013-10-21 CO CO13249372A patent/CO6831982A2/es unknown
- 2013-10-21 CR CR20130536A patent/CR20130536A/es unknown
- 2013-10-21 CL CL2013003051A patent/CL2013003051A1/es unknown
- 2013-10-21 CU CU2013000143A patent/CU20130143A7/es unknown
- 2013-10-21 ZA ZA2013/07839A patent/ZA201307839B/en unknown
- 2013-10-21 EC ECSP13012982 patent/ECSP13012982A/es unknown
- 2013-11-14 MA MA36430A patent/MA35124B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35124B1 (fr) | Pyrazolo[4,3-d] | |
| MA35123B1 (fr) | Composes heterocycliques en tant qu'inhibiteurs de kinases | |
| EA201270480A1 (ru) | Новые соединения | |
| MX354412B (es) | Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton. | |
| PH12016502060A1 (en) | Processes for preparing jak inhibitors and related intermediate compounds | |
| UA113186C2 (xx) | Макроциклічні інгібітори lrrk2 кінази | |
| WO2015006754A3 (en) | Pyrimidine derivatives as kinase inhibitors | |
| EA201592146A1 (ru) | Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам | |
| WO2009067493A3 (en) | 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders | |
| HK1216425A1 (zh) | 基於2，3-二氢咪唑并[1，2-c]嘧啶-5(1h)-酮的脂蛋白相关磷脂酶a2(lp-pla2)抑制剂 | |
| EA201390710A1 (ru) | Производные бензодиазепина, композиции и способы для лечения когнитивного нарушения | |
| EP4327884A3 (en) | 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as lrrk2, nuak1 and/or tyk2 kinase modulators for the treatment of e.g. autoimmune diseases | |
| AR086196A1 (es) | Derivados de pirazolo[3,4-c]quinolina, inhibidores de quinasa | |
| EA201591021A1 (ru) | 4-гидрокси-2-метил-5-(пропан-2-илиден)циклогекс-3-энекарбальдегид в профилактике и лечении когнитивных, нейродегенеративных или нейронных заболеваний | |
| MX362862B (es) | Derivados de 1,3-difenilpropano, preparaciones y usos de los mismos. | |
| EA201001775A1 (ru) | СИНТЕЗ ДИГИДРОТИЕНО[3,2-d]ПИРИМИДИНДИОЛОВ И СХОДНЫХ ПИРИМИДИНДИОЛОВ | |
| WO2006087634A3 (en) | Uses of human autism susceptibility gene encoding a kinase | |
| WO2011015646A3 (en) | Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders | |
| TN2010000521A1 (en) | Synthesis of dihydrothieno [3,2-d] pyrimidine diols and similar pyrimidine diols | |
| TH115252A (th) | กรรมวิธีสำหรับการเตรียมตัวยับยั้ง jak และสารประกอบตัวกลางที่เกี่ยวข้อง | |
| UA106368C2 (en) | 1-heterocyclyl-1,5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators | |
| EA201691232A1 (ru) | Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений | |
| EA201400009A1 (ru) | Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений |